GLUE logo

Monte Rosa Therapeutics Inc. (GLUE)

$9.07

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GLUE

Market cap

$775032579

EPS

-1.4

P/E ratio

--

Price to sales

30.59

Dividend yield

--

Beta

1.40833

Price on GLUE

Previous close

$9.16

Today's open

$9.19

Day's range

$8.83 - $9.28

52 week range

$8.83 - $25.77

Profile about GLUE

CEO

Markus Warmuth

Employees

150

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

85450119

Issue type

Common Stock

GLUE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on GLUE

Monte Rosa Therapeutics: The Market Is Punishing NEK7 For IL-6's Failure

Monte Rosa Therapeutics looks mispriced after ZEUS's failure drove a weak read-through to its differently targeted NEK7 degrader, MRT-8102. Gout offers the nearer value inflection: GEMINI-1 initial clinical data are expected in H2 2027, ahead of cardiovascular outcomes. GLUE's approximately $220 million enterprise value sits below one-quarter of Lilly's $1.2 billion Ventyx deal, despite its pipeline and Novartis partnership.

news source

Seeking Alpha • Nov 17, 2026

news preview

Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis

Monte Rosa Therapeutics, Inc. remains a risky Buy despite nearly 50% share-price losses since my initial recommendation. MRT-8102's promising biomarker data support further study, although ziltivekimab's failure has weakened market confidence in inflammation-targeting cardiovascular drugs. GLUE's roughly $580 million cash balance leaves its pipeline valued at approximately $215 million, but clinical failures and cash burn remain significant risks.

news source

Seeking Alpha • a day ago

news preview

Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcript

Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout

NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis, supporting the Company's planned Phase 2 study in patients with gout.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key  pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo; Phase 2 initiation in coronary artery disease anticipated in H1 2027 Initiation of Phase 2 study of MRT-8102 in gout expected in Q4 2026, with data update expected in H2 2027; additional Phase 2 initiation in hidradenitis suppurativa anticipated in H1 2027 Initiated MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations; Phase 2 data update expected in 2027; updated Phase 1/2 study data expected this year Novartis initiated Phase 2a/b studies of VAV1-directed MGD MRT-6160 (DDY391) in Sjögren's disease and psoriatic arthritis, triggering a total of $87.5 million in Phase 2 milestone payments to date to Monte Rosa Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $582.6 million (not including MRT-6160 Phase 2 initiation milestones) as of September 30, 2026, expected to support operations into 2029 BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced business highlights and financial results for the third quarter ended September 30, 2026. “The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies,” said Markus Warmuth, M.D.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 33,775 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $10.63 as reported by Nasdaq on November 2, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 7,400 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

The consensus price target hints at a 152.9% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ET UBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Monte Rosa Therapeutics Inc.

Open an M1 investment account to buy and sell Monte Rosa Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GLUE on M1